Women aged 18 to 45 years with IBD were invited to complete a survey regarding knowledge, attitude, and beliefs about contraception.

The trial is anticipated to enrol 462 subjects and aims to confirm the safety and efficacy of the combination.

Baseline histologic activity predicted colectomy risk in ulcerative colitis treated with biologics, independent of clinical or endoscopic factors.

Intestinal fibrosis, as a late-stage complication of inflammatory bowel disease (IBD), leads to bowel obstruction and requires surgical intervention, significantly lowering the quality of life of ...

Eli Lilly has received approval from the US Food and Drug Administration (FDA) for Omvoh (mirikizumab-mrkz) to treat moderately to severely active Crohn's disease in the adult population. This is the ...

From the biologics’ first US Food and Drug Administration (FDA ... with the company highlighting how the two products have captured around 50% of the market share in IBD indications such as Crohn’s ...

From the biologics’ first US Food and Drug Administration ... two products have captured around 50% of the market share in IBD indications such as Crohn’s disease and ulcerative colitis.

This is its second indication. In 2023, it was approved as a first-in-class treatment for moderate to severe ulcerative colitis in adults ... immunomodulators and/or biologics. About 1 million people ...

A RECENT study has revealed that the sequence of biologic treatments in patients with inflammatory bowel disease (IBD) significantly affects their risk of adverse clinical outcomes. Patients with IBD, ...

The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products. Below is a review of novel drug and biological products approved by the Food and Drug ...